Left Ventricular Assist Devices (LVAD) for Heart Conditions - Healthline

Left ventricular assistance devices (LVADs) are small, battery-operated pumps implanted into the chest to help the heart circulate blood. They're used to help people with end-stage heart failure, either to improve survival while waiting for a heart transplant or as the primary treatment.

The LVAD pump is attached to a controller with a cable that runs through a small port in your skin. LVADs have traditionally been implemented with open-heart surgery, but minimally invasive procedures are becoming more common.

The first LVAD was implemented in 1963, and now the annual number of LVAD implantations far exceeds the number of heart transplants.

Read on to learn how LVADs work, who they can help, and potential complications.

Your heart has four chambers. The top two chambers are called atriums and the bottom two are called ventricles.

Your left ventricle is responsible for pumping oxygenated blood from your heart to the major blood vessel that carries blood away from your heart called your aorta.

LVADs act as a partial artificial heart in people whose hearts are too weak to pump blood efficiently by themselves. They help pump oxygenated blood from your left ventricle into your aorta.

The basic design of LVADs has remained the same since they were FDA-approved in 1994. They usually have four main parts:

  • Pump. A tube is placed inside your left ventricle. Blood travels through this tube, into a pump just below your heart, and into your aorta through another tube.
  • Driveline. The driveline is a cable that connects the pump to the controller. It travels through a hole in your abdomen.
  • Controller. The controller powers the pump and gives you updates about whether the system is working properly.
  • Batteries. Two batteries power the controller when it's not plugged in. The batteries can be carried on a belt, harness, or backpack.

LVADs are used to help manage end-stage heart failure.

Heart disease is the leading cause of death in the United States. The most common type of heart disease is called coronary artery disease, which is when the blood vessels that supply your heart become clogged. It's almost always caused by a buildup of plaque or cholesterol.

When your coronary arteries become clogged, your heart is unable to pump blood adequately, which is known as heart failure.

The American Heart Association (AHA) has estimated that 5.1 million people are living with heart failure in the United States.

Heart failure tends to gradually get worse over time. It's known as end-stage heart failure if it progresses to the point where your heart can't pump enough blood to meet your body's needs.

At this point, it causes symptoms such as:

Heart transplantation is still considered the gold standard for end-stage heart failure, but the number of transplantations is limited by the number of donor hearts available. LVADs can be lifesaving for some people and are used in four main ways.

Bridge to transplantation

LVADs can provide support for people waiting for a heart to become available for transplantation. Research has found that bridge-to-transplant LVADs provide excellent survival and similar quality of life to people who receive heart transplants right away.

Destination therapy

Destination therapy is when an LVAD is used as the primary treatment. It's used in people who aren't eligible for a heart transplant. Technological improvements have led to increased survival for people who receive destination therapy LVADs.

Bridge to the decision

People with end-stage organ failure due to heart failure are ineligible for heart transplants. LVADs can help stabilize organ failure to make them eligible for a transplant in the future.

Bridge to recovery

LVADs can provide temporary heart support for some people with heart failure and help promote recovery of heart function.

People with late-stage heart failure often experience less fatigue, more strength, and better breathing after receiving an LVAD.

In a 2017 study analyzing data from more than 20,000 people, researchers found 1-year and 2-year overall survival rates of 80 percent and 70 percent respectively in people with continuous-flow LVADs. Continuous flow implants make up more than 95 percent of current LVADs.

A 2021 study found that of 157 people with LVAD implants, 92 died after 5 years. However, in 67.2 percent of these people, the cause of death wasn't cardiovascular. The average age of the people in the study was nearly 51.

According to the AHA, about half of people with LVADs receive them as destination therapies and 26 percent receive them for bridge-to-transplant.

Outcomes are currently more favorable for people who receive them as bridge-to-transplant. About 30 percent of people receive a heart within 1 year and 77 percent survive for at least 2 years.

People receiving an LVAD as a destination therapy tend to have more health complications but 68 percent of people live at least 2 years.

Survival rates have increased as technology improves, and likely will continue to do so in the future.

LVADs have traditionally been implanted with open-heart surgery, but minimally invasive surgical techniques are becoming more common. LVADs continue to get smaller, making minimally invasive surgery a more practical option.

Conventional open-heart surgery

During open-heart surgery, you'll likely experience something like this:

  1. You'll be put asleep with anesthesia administered through an IV.
  2. Your surgeon will make a large incision on your breastbone to access your heart by spreading your rib cage.
  3. A cardiopulmonary bypass machine will take over the work of your lung and heart.
  4. The surgeon will connect one end of the LVAD tube to your heart's left ventricle and the other end to your aorta. The driveline is connected to the pump and to batteries or a plug.
  5. Once your device is working correctly, you'll be taken off the cardiopulmonary bypass machine and your chest is closed with stitches.

Open-heart surgery usually takes 4 to 6 hours.

Minimally invasive alternatives

There are also various minimally invasive surgical techniques that are currently used or are under investigation. During a minimally invasive procedure, your doctor will make one or more smaller incisions to access your heart.

For example, during a thoracotomy procedure, the procedure is performed through the ribs instead of through the breastbone.

Despite the potential benefits of LVADs, every surgery comes with risk.

Here's a look at some of the complications of LVADs along with their reported rates, according to a 2015 review:

LVADs are expected to continue to get smaller over time and minimally invasive surgery is becoming more common. Minimally invasive LVAD surgery is expected to become the standard of care, making LVADs more widely available at considerably lower risk.

LVADs are mechanical pumps implanted below the heart to treat late-stage heart failure. They're used to treat people waiting for heart transplants or people ineligible for transplants. Many people experience an improvement in quality of life after receiving an LVAD.

The LVAD procedure comes with potential complications such as heavy bleeding or infection. Minimally invasive surgical techniques are becoming more popular and tend to cause fewer complications than traditional open-heart surgery.

The best way to know if you might benefit from an LVAD is by discussing it with your doctor. Your doctor can help you understand if you're eligible and help you weigh pros and cons.

Comments

Post a Comment

Popular posts from this blog

Epoprostenol Via High-Flow Nasal Cannula Improves Severe Hypoxemia in PH - Pulmonology Advisor

Image
Epoprostenol Via High-Flow Nasal Cannula Improves Severe Hypoxemia in PH - Pulmonology Advisor Epoprostenol Via High-Flow Nasal Cannula Improves Severe Hypoxemia in PH - Pulmonology Advisor Posted: 11 Jul 2019 12:00 AM PDT For patients with severe hypoxemia with pulmonary hypertension or right heart dysfunction, inhaled epoprostenol through high-flow nasal cannula increases oxygenation, according to a study published in Pharmaceutics . The researchers of this retrospective study assessed the effect of inhaled epoprostenol using a high-flow nasal cannula on oxygenation and future mechanical ventilation in patients with hypoxemia comorbid with pulmonary hypertension or right heart dysfunction in an intensive care unit setting. A chart review was completed on adult patients who were admitted into the respiratory care department of the Rush University Medical Center for severe hypoxemia between July 2015 and April 2018 and treated with inha...
Read more

Novitium's Generic Sildenafil for PAH Treatment Approved by FDA - Pulmonary Hypertension News

Image
Novitium's Generic Sildenafil for PAH Treatment Approved by FDA - Pulmonary Hypertension News Novitium's Generic Sildenafil for PAH Treatment Approved by FDA - Pulmonary Hypertension News Growing Doubt, Uncertainty Over PDE5i Use in Left Heart Disease - Medscape AnMed Health gains national recognition through the Pulmonary Hypertension Association - WSPA.com Novitium's Generic Sildenafil for PAH Treatment Approved by FDA - Pulmonary Hypertension News Posted: 12 Jun 2019 05:00 AM PDT The U.S. Food and Drug Administration (FDA) has approved Novitium Pharma 's generic sildenafil for oral suspension at a dose of 10 mg/mL for the treatment of pulmonary arterial hypertension (PAH). This product, which had been designated a competitive generic therapy by the FDA, is the first approved generic equivalent to Pfizer 's Revatio , a vasodilator agent that induces blood ves...
Read more

Analysis: Large pharma companies do little new drug innovation - STAT

Image
Analysis: Large pharma companies do little new drug innovation - STAT Analysis: Large pharma companies do little new drug innovation - STAT Gene Therapy Takes Center Stage at 2019 NORD Summit - Pulmonary Hypertension News People Living With Type 2 Diabetes Want Information and Empathy From Their Doctors More Than New Medications - PRNewswire Analysis: Large pharma companies do little new drug innovation - STAT Posted: 10 Dec 2019 01:51 AM PST L arge pharmaceutical companies oppose legislation being considered by Congress to lower the prices of prescription drugs. Reducing their revenues, they contend, will reduce their investment in drug development and the discovery of new medicines, and thus lead to a decline in drug innovation. If that argument is credible, there should be evidence to show that the large pharmaceutical companies are responsible for discovering innovative new drugs. To test that claim, we examined the...
Read more